The diagnostic codes contained in this section are designed to provide important reimbursement information that will be helpful for your pharmacy when ordering INQOVI. ICD codes continually change, so it is recommended that you consult your ICD-10 code book or contact the payer for coding and billing guidance.
35 mg decitabine and 100 mg cedazuridine
5-tablet blister pack
Please contact an authorized distributor or one of the specialty pharmacies listed on the Specialty Pharmacies tab for AWP and WAC pricing.
AWP=average wholesale price; NDC=National Drug Code; WAC=wholesale acquisition cost.
Diagnosis codes for Myelodysplastic Syndromes (MDS)
Refractory anemia without ring sideroblasts, so stated
Refractory anemia without sideroblasts, without excess of blasts
Refractory anemia with ring sideroblasts RARS
Refractory anemia with excess of blasts RAEB
Refractory anemia with excess of blasts, unspecified RAEB NOS
Refractory anemia with excess of blasts 1 RAEB 1
Refractory anemia with excess of blasts 2 RAEB 2
Refractory cytopenia with multilineage dysplasia
Refractory cytopenia with multilineage dysplasia and ring sideroblasts RCMD R5
Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality
Myelodysplastic syndrome with 5q deletion 5q minus syndrome NOS
Refractory Anemia, unspecified
Other myelodysplastic syndromes EXCLUDES chronic myelomonocytic leukemia (C93.1-)
Myelodysplastic syndrome, unspecified
ICD‑10‑CM EXPERT: Diagnosis codes for Providers & Facilities, AAPC, 2020, p. 505. This information is not intended as coverage or coding advice and does not guarantee reimbursement. You should verify the appropriate reimbursement information for services or items you provide. Each healthcare professional is responsible for ensuring that all coding is accurate and appropriate.
Diagnosis codes for Chronic Myelomonocytic Leukemia (CMML)
Chronic myelomonocytic leukemia
Chronic monocytic leukemia
CMML with eosinophilia
Chronic myelomonocytic leukemia not having achieved remission
Chronic myelomonocytic leukemia with failed remission
Chronic myelomonocytic leukemia NOS
Chronic myelomonocytic leukemia, in remission
Chronic myelomonocytic leukemia, in relapse
ICD‑10‑CM EXPERT: for Providers & Facilities, AAPC, 2020, p. 494.
INQOVI is indicated for treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated,de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringedsideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2,and high-risk International Prognostic Scoring System groups.
Taiho Oncology Patient Support™ for you and your patients
Taiho Oncology Patient Support™ offers personalized services to help give patients, caregivers and healthcare
professionals access to Taiho Oncology products. This includes
insurance coverage determination and help with medication affordability. For more information, please
visit or refer patients to TaihoPatientSupport.com
Meeting the access needs of your patients Getting
patients access to their medicine is an important step. Taiho Oncology Patient Support™ strives to make this process as simple as
Help Accessing Prescribed Treatment*
Assistance with insurance, including benefits verification, prior authorization, appeals support, and more.
$0 Co-Pay Financial Assistance*†
Identifying options for financial support based on current coverage. See below for more details.
One-on-one educational support for patients, available via opt-in.
†Restrictions and eligibility: Offer valid in the US, Puerto Rico, and US territories only. Only valid for patients with private insurance. Offer not valid for prescriptions reimbursed under Medicaid, a Medicare drug benefits plan, Tricare, or other federal or state programs (such as medical assistance programs). If the patient is eligible for drug benefits under any such program, this offer is not valid and the patient cannot use this offer. By presenting or accepting this benefit, patient and pharmacist agree not to submit claim for reimbursement under the above programs. Patient further agrees to comply with any and all terms of his or her health insurance contract requiring notification to his or her payer for the existence and/or value of this offer. It is illegal to or offer to sell, purchase, or trade this benefit. Maximum reimbursement limits apply; patient out-of-pocket expense may vary. Taiho Oncology, Inc. reserves the right to rescind, revoke or amend this offer at any time without notice.
‡If selected on the Patient Enrollment Form, a Nurse Navigator will be
assigned to provide telephone support and will address general inquiries about INQOVI treatment.
INQOVI Treatment Kit
The INQOVI Treatment Kit provides support for patients and
The kit includes:
A comprehensive patient brochure
Accompanying caregiver brochure
Blister pack opener with instruction card
Advocacy support brochure
Patient advocacy organizations
These organizations offer patients information, support, and community. Feel free to
share the following resources with your patients:
The Myelodysplastic Syndromes (MDS) Foundation
Myelosuppression: Fatal and serious myelosuppression can occur with INQOVI. Based on laboratory values, new or worsening thrombocytopenia occurred in 82% of patients, with Grade 3 or 4 occurring in 76%. Neutropenia occurred in 73% of patients, with Grade 3 or 4 occurring in 71%. Anemia occurred in 71% of patients, with Grade 3 or 4 occurring in 55%. Febrile neutropenia occurred in 33% of patients, with Grade 3 or 4 occurring in 32%. Myelosuppression (thrombocytopenia, neutropenia, anemia, and febrile neutropenia) is the most frequent cause of INQOVI dose reduction or interruption, occurring in 36% of patients. Permanent discontinuation due to myelosuppression (febrile neutropenia) occurred in 1% of patients. Myelosuppression and worsening neutropenia may occur more frequently in the first or second treatment cycles and may not necessarily indicate progression of underlying MDS.
Fatal and serious infectious complications can occur with INQOVI. Pneumonia occurred in 21% of patients, with Grade 3 or 4 occurring in 15%. Sepsis occurred in 14% of patients, with Grade 3 or 4 occurring in 11%. Fatal pneumonia occurred in 1% of patients, fatal sepsis in 1%, and fatal septic shock in 1%.
Obtain complete blood cell counts prior to initiation of INQOVI, prior to each cycle, and as clinically indicated to monitor response and toxicity. Administer growth factors and anti-infective therapies for treatment or prophylaxis as appropriate. Delay the next cycle and resume at the same or reduced dose as recommended.
Embryo-Fetal Toxicity: INQOVI can cause fetal harm. Advise pregnant women of the potential risk to a fetus. Advise patients to use effective contraception during treatment and for 6 months (females) or 3 months (males) after last dose.
Serious adverse reactions in > 5% of patients included febrile neutropenia (30%), pneumonia (14%), and sepsis (13%). Fatal adverse reactions included sepsis (1%), septic shock (1%), pneumonia (1%), respiratory failure (1%), and one case each of cerebral hemorrhage and sudden death.
The most common adverse reactions (≥ 20%) were fatigue (55%), constipation (44%), hemorrhage (43%), myalgia (42%), mucositis (41%), arthralgia (40%), nausea (40%), dyspnea (38%), diarrhea (37%), rash (33%), dizziness (33%), febrile neutropenia (33%), edema (30%), headache (30%), cough (28%), decreased appetite (24%), upper respiratory tract infection (23%), pneumonia (21%), and transaminase increased (21%). The most common Grade 3 or 4 laboratory abnormalities (≥ 50%) were leukocytes decreased (81%), platelet count decreased (76%), neutrophil count decreased (71%), and hemoglobin decreased (55%).
Use in Specific Populations
Lactation: Because of the potential for serious adverse reactions in the breastfed child, advise women not to breastfeed during treatment with INQOVI and for 2 weeks after the last dose.
Renal Impairment: No dosage modification of INQOVI is recommended for patients with mild or moderate renal impairment (creatinine clearance [CLcr] of 30 to 89 mL/min based on Cockcroft-Gault). Due to the potential for increased adverse reactions, monitor patients with moderate renal impairment (CLcr 30 to 59 mL/min) frequently for adverse reactions. INQOVI has not been studied in patients with severe renal impairment (CLcr 15 to 29 mL/min) or end-stage renal disease (ESRD: CLcr <15 mL/min).